Radiopharmaceutical · developed by Lantheus Biosciences
BAY86-9596 is an F-18 labeled radiopharmaceutical given as a single intravenous bolus for whole body PET/CT imaging.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01089998 | Phase 1 | Diagnostic Imaging | Completed | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diagnostic Imaging
Updated Nov 15, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →